Vismodegib

Vismodegib
Clinical data
Pronunciation	/ˌvɪsmoʊˈdɛɡɪb/ ; VIS-moh-DEG-ib
Trade names	Erivedge
Other names	GDC-0449, RG-3616
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN ; US FDA: Vismodegib ;
Pregnancy; category	AU:X (High risk);
Routes of; administration	By mouth
ATC code	L01XJ01 ( WHO );
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only ; UK: POM (Prescription only); US: ℞-only ; EU:Rx-only;
Pharmacokinetic data
Bioavailability	31.8%
Protein binding	>99%
Metabolism	<2% metabolised by CYP2C9, CYP3A4, CYP3A5
Elimination half-life	4 days (continuous use),; 12 days (single dose)
Excretion	Fecal (82%), Urinary (4.4%)
Identifiers
	IUPAC name 2-Chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide;
CAS Number	879085-55-9 ;
PubChem CID	24776445 ;
IUPHAR/BPS	6975 ;
DrugBank	DB08828 ;
ChemSpider	23337846 ;
UNII	25X868M3DS ;
KEGG	D09992 ;
ChEBI	CHEBI:66903 ;
ChEMBL	ChEMBL473417 ;
CompTox Dashboard (EPA)	DTXSID40236689 ;
ECHA InfoCard	100.234.019
Chemical and physical data
Formula	C19H14Cl2N2O3S
Molar mass	421.29 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl;
	InChI InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24); Key:BPQMGSKTAYIVFO-UHFFFAOYSA-N;

Last updated July 17, 2025

Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC).^[2] The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.^[3] The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma as of June 2011^[update].^[4] The drug was developed by the biotechnology/pharmaceutical company Genentech.^[3]

Indication

Vismodegib is indicated for people with basal-cell carcinoma (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.^[3]^[5]

Mechanism of action

The substance acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the Hedgehog signaling pathway.^[4] SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway.^[6] This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.^[7]

Side effects

In clinical trials, common side effects included gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation), muscle spasms, fatigue, hair loss, and dysgeusia (distortion of the sense of taste).^[2]

Development

Vismodegib has undergone several promising phase I and phase II clinical trials for its use in treating medulloblastoma.^[8]

References

1 2 "Erivedge® (vismodegib)". Australian Prescribing Information, Australian Register of Therapeutic Goods (ARTG). Roche Products Pty Limited. 17 November 2022.
1 2 3 "Erivedge- vismodegib capsule". DailyMed. U.S. National Library of Medicine. 9 April 2019. Retrieved 8 January 2023.
1 2 3 "FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma". Roche. 30 January 2012. Retrieved 9 August 2020.
1 2 "Vismodegib". Molecule of the Month. Prous Science. June 2011. Archived from the original on 27 September 2011.
↑ Lacroix M (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. Archived from the original on 2015-06-26. Retrieved 2014-07-13.
↑ "Vismodegib (GDC-0449) Smoothened Inhibitor". BioOncology. Genentech. Archived from the original on 4 June 2011.
↑ Spreitzer H (4 July 2011). "Neue Wirkstoffe – Vismodegib". Österreichische Apothekerzeitung (in German) (14/2011): 10.
↑ Li Y, Song Q, Day BW (July 2019). "Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis". Acta Neuropathologica Communications. 7 (1): 123. doi: 10.1186/s40478-019-0773-8 . PMC 6668073 . PMID 31362788.

External links

"Vismodegib". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on January 18, 2017.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[Erivedge_PI-1] 1 2 "Erivedge® (vismodegib)". Australian Prescribing Information, Australian Register of Therapeutic Goods (ARTG). Roche Products Pty Limited. 17 November 2022.

[Erivedge_FDA_label-2] 1 2 3 "Erivedge- vismodegib capsule". DailyMed. U.S. National Library of Medicine. 9 April 2019. Retrieved 8 January 2023.

[Roche_PR-3] 1 2 3 "FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma". Roche. 30 January 2012. Retrieved 9 August 2020.

[Prous-4] 1 2 "Vismodegib". Molecule of the Month. Prous Science. June 2011. Archived from the original on 27 September 2011.

[5] Lacroix M (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. Archived from the original on 2015-06-26. Retrieved 2014-07-13.

[6] "Vismodegib (GDC-0449) Smoothened Inhibitor". BioOncology. Genentech. Archived from the original on 4 June 2011.

[Spreitzer-7] Spreitzer H (4 July 2011). "Neue Wirkstoffe – Vismodegib". Österreichische Apothekerzeitung (in German) (14/2011): 10.

[8] Li Y, Song Q, Day BW (July 2019). "Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis". Acta Neuropathologica Communications. 7 (1): 123. doi: 10.1186/s40478-019-0773-8 . PMC 6668073 . PMID 31362788.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]